Statins for the prevention of dementia.
Level 1 - systematic review of randomized trials
Systematic review of randomized controlled trials
PubMed 26727124 · doi:10.1002/14651858.CD003160.pub3
What was done
Authors conducted a Cochrane systematic review searching multiple databases through November 2015 for double-blind, randomized, placebo-controlled trials administering statins for at least 12 months to individuals at risk of dementia. Two trials evaluating simvastatin and pravastatin met inclusion criteria, enrolling 26,340 participants aged 40 to 82 years (11,610 aged 70 or older) with vascular disease or vascular risk factors, followed for a mean of 3.2 and 5.0 years.
What was found
Only one study reported dementia incidence (20,536 participants; 31 cases per group), showing no reduction with statins (OR 1.00, 95% CI 0.61 to 1.65; moderate-quality evidence downgraded for imprecision). Cognitive function measures from both trials could not be pooled due to differing scales and assessment schedules, but no differences between statin and placebo groups were observed across five cognitive tests (high-quality evidence). Treatment discontinuation due to non-fatal adverse events was under 5% in both trials, with no difference between groups (26,340 participants, 2 studies, OR 0.94, 95% CI 0.83 to 1.05).
Why it matters
This review shows that observational associations linking statin use to reduced dementia risk are not supported by randomized trial evidence, likely reflecting indication bias in earlier observational cohorts.
Limits
Only two trials met inclusion criteria and only one measured clinical dementia incidence, resulting in wide confidence intervals and imprecision. Cognitive outcomes could not be meta-analyzed due to heterogeneous tests and timing. Participants were restricted to individuals with moderate-to-high vascular risk, and follow-up was limited to 3.2 to 5 years.
Cited by
- supports There has never been a clinical study evaluating statin use that had the incidence of Alzheimer's disease or dementia as a primary outcome.
- supports Clinical trials that measured dementia or Alzheimer's disease as secondary outcomes consistently found neutral to beneficial effects of statin use on dementia and Alzheimer's disease incidence.